Abstract
Hypoxia-mimicking agents (HMAs) exert distinct proliferative effect on breast cancer cells depending on the subtype. Pharmacological HIF activation via PHD inhibition enhances the proliferation rate of triple negative MDA-MB-231 cells but inhibits proliferation of receptor-positive MCF7 cells. Therefore, clinical PHD inhibitors should be used with caution as they may be a double-edged sword, acting as anticancer agents or tumorigenic drivers depending on the breast cancer subtype.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
